

BIMZELX[®] (bimekizumab-bkzx) Reference Document- Axial Spondyloarthritis

BIMZELX[®] is indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. See [Full Prescribing Information](#) for additional details.

This document contains information on the use of bimekizumab in disease states where the safety and efficacy have not been established. BIMZELX[®] is not currently approved for the treatment of non-radiographic axial spondyloarthritis or ankylosing spondylitis.

Axial Spondyloarthritis Manuscripts

[BE MOBILE 1 AND 2 \(16WK\)](#)

Van der Heijde D, Deodhar A, Baraliakos X et al. Efficacy of safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. *Ann Rheum Dis* 2023; 82: 515-526.

Synopsis: Parallel studies evaluating safety and efficacy of bimekizumab in non-radiographic axial spondyloarthritis and radiographic axial spondyloarthritis (ankylosing spondylitis). Primary endpoints were ASAS40 response at week 16. Additional analyses include ASAS20, BASDI and safety.

[BE MOBILE 1 AND 2 \(52 WK\)](#)

Baraliakos, X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. *Ann Rheum Dis* 2024; 83: 199-213.

Synopsis: Parallel studies evaluating safety and efficacy of bimekizumab in non-radiographic axial spondyloarthritis and radiographic axial spondyloarthritis (ankylosing spondylitis). Safety and efficacy results reported to week 52.

[WORK PRODUCTIVITY IN AXSPA](#)

Rudwaleit M, Morup M, Humphries B, et al. Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis. *RMD Open* 2023; 9:e003468.